Business, energy, technology, markets and global industry news from Business News Today

KIMMTRAK

PharmaDeviceNews KIMMTRAK
A clinician-scientist reviews ocular imaging as DYP688 Phase 1 results highlight early targeted activity in metastatic uveal melanoma, even as the drug’s future development remains uncertain. Representative image.
Pharma & Biotech

A promising eye cancer drug shrank tumors in phase 1, so why did Novartis stop developing DYP688?

DYP688 showed early activity and manageable toxicity in metastatic uveal melanoma, but Novartis has halted development despite the clinical signal.

Read More
Pharma & Biotech

Could five-year survival data position KIMMTRAK as a durable standard in uveal melanoma care

Discover how Immunocore’s five-year KIMMTRAK data could reshape survival expectations in metastatic uveal melanoma. Read the full analysis.

Read More